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Complement activation in IgA nephropathy. Activation of alternative
complement pathway is presumed to be important pathogenically in IgA
nephropathy since renal biopsies usually exhibit glomerular deposition
of C3 and P (properdin). Surprisingly, little is known about plasma
complement activation in this disease, and the plasma C3 and C4
concentrations are usually normal or increased. We quantitated C3
activation in 202 plasmas from 81 patients with IgA nephropathy using
a sensitive new assay that detects a neoantigen ((iC3b-C3d neoantigen)
which appears when C3b is inactivated to iC3b, C3dg, or C3d. This
assay accurately quantitates small amounts of in vivo C3 activation.
The concentration of iC3b-C3d neoantigen in plasma was significantly
increased, indicating C3 activation in 37% of the pediatric and 57% of
the adult plasmas assayed. When data from serial determinations in the
patients were analyzed, 75% of the adult and 57% of the pediatric
patients had C3 activation on at least one occasion. Classical pathway
activation, quantitated by C4 activation was found in 20% of the adult
and 5% of the pediatric plasmas. No association was found between
elevated iC3b-C3d neoantigen concentration and history of macro-
scopic hematuria, chronic renal insufficiency or degree of proteinuria.
These studies show that complement activation can frequently be
detected in the plasma of IgA nephropathy patients. However, the
pathophysiologic significance of this complement activation remains to
be determined.
Immunohistologic studies of the mesangial deposits in IgA
nephropathy typically reveal C3 and P (properdin) in a pattern
similar to IgA [1—8]. The classical complement pathway pro-
teins Clq and C4 are usually absent [2—8]. These findings have
suggested a pathogenic role for the alternative complement
pathway in this disease [1, 2]. Subseqently, Tomino, Endoh and
Nomoto showed that renal tissue from patients with IgA
nephropathy will activate the alternative pathway of comple-
ment [9].
Mild, but significant elevation of plasma concentrations of the
C3d fragment has previously been found in some patients with
IgA nephropathy [10, 11]. However, serum or plasma concen-
trations of C3, C4, and other complement proteins are normal
or elevated in these patients, except in the unusual instances of
a familial complement deficiency [12—14]. No data are available
on C4 activation fragments in IgA nephropathy.
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The purpose of this study was to examine whether or not
complement activation is detectable in plasma from patients
with IgA nephropathy. A sensitive new assay with a unique
monoclonal antibody directed toward a determinant expressed
on the degradation fragments of C3 was used.
Methods
Patients
For the study, 202 plasmas were obtained from 81 patients
with IgA nephropathy followed in Lexington, Kentucky or
LeBonheur Children's Medical Center, Memphis, Tennessee.
Fifty—three patients were adults (over 18 years) and 26 were
pediatric (under 18 years) for all studies. Two patients were
studied in both age groups. The male to female ratio was 53:28.
Twenty—eight patients had a single plasma assayed, 24 patients
had two, and 29 patients had three to nine.
Seventy—eight patients were Caucasian, two were Black and
one was Indonesian. The diagnostic criteria for IgA nephrop-
athy were: I) there was no laboratory or clinical evidence of
liver disease, systemic lupus erythematosus, chronic inflamma-
tory conditions of the skin, gastrointestinal tract or respiratory
tract or neoplasm; 2) immunohistologic staining of the glomeruli
found IgA in a predominately mesangial pattern; 3) electron
microscopy, performed in most patients, showed mesangial or
paramesangial electron—dense deposits.
No patient was receiving dialytic or immunosuppressive
therapy at the time of blood sampling. Clinical data such as
episodes of macroscopic hematuria, proteinuria (either dipstick
or 24 hour quantitation), microscopic hematuria and serum
creatinine concentration were recorded on the sampling dates.
Chronic renal insufficiency was defined by a serum creatinine
concentration persistently above 1.4 mg/dl.
Plasmas were collected by venipuncture into EDTA-Na
containing tubes, usually at the time of routine office visit. In
most cases no intercurrent infection was evident. The plasmas
were aliquoted and stored at —70°C prior to performance of the
assays.
Radioimmunoassay for iC3b-C3d neoantigen
A murine monoclonal antibody (MoAb 130) specific for a
neoantigen expressed on iC3b, C3dg and C3d fragments of C3
was purified from ascites by protein A (protein A-CL-Sep-
harose 4B, Pharmacia Fine Chemicals, Piscataway, New Jer-
sey) affinity chromatography [15]. Purified MoAb 130 reacts
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minimally (<1% molJmol) or not at all with C3, C3b or C3c [15].
MoAb 130 was radiolabelled with 1251 as previously described
[16] and stored in aliquots at —20°C until used in the radio-
immunoassay.
Microtiter solid—phase radioimmunoassay was performed as
previously described [17] using polyvinyl—chloride microtiter
plates incubated with purified C3 and C3 fragments overnight
and with 1% bovine serum albumin (BSA) in phosphate buff-
ered saline (PBS) for two hours to block nonspecific protein
binding sites. The coated-BSA blocked plates were stored at
4°C until used (usually within one week). For determination of
iC3b-C3d neoantigen concentration, plasmas were diluted 1: 10
in 0.1% BSA in PBS with 50 microliters and added in triplicate
to the C3 coated wells. In addition to the diluted plasma
samples, known amounts of purified iC3b were added to wells
on the same plate for generation of a standard curve. The 125J
labelled MoAb 130 was thawed, diluted, added to each well and
incubated at 4°C overnight. After the wells were extensively
washed with PBS, they were cut out and counted in a gamma
counter. The amounts of iC3b-C3d neoantigens were expressed
as iC3b-C3d equivalents after comparison to the standard curve
for purified iC3b. The normal range for iC3b-C3d neoantigen
concentration in plasma, determined by mean two SD for 31
healthy adults, was 8.6 to 22.6 pg/mi.
Rocket immunoelectrophoresis for C4d and C4
To assess classical complement pathway, activation rocket
immunoelectrophoresis for C4 and C4d was performed as
previously described [18, 19]. The concentration of C4d in a
plasma sample was calculated by dividing the area under the arc
produced by C4d by the area under the arc produced by C4
(C4dJC4 ratio). The areas were measured by planimetry of
enlarged photographs of the slides. The antiserum recognized
both C4d and native C4. An area C4/area C4d ratio of 1.00
indicates that no C4d is detectable. Control plasmas from 22
healthy volunteers showed 19 with no detectable C4d and three
with small amounts.
Plasma concentrations of complement proteins and IgA
Plasma concentrations of C3, B, P. H (/31H) and I (C3b
inactivator) were measured by radial immunodiffusion utilizing
monospecific antiserums as previously described [14]. Plasma
concentration of IgA was determined by radial immunodiffusion
using plates and standards purchased commercially (Kallestad
Laboratories, Inc., Chaska, Minnesota, USA).
Sucrose gradient ultracentrifugation
Linear 10 to 40% wt/vol sucrose gradients (11 ml total
volume) were prepared in 0.1% BSA in PBS. Plasmas from
three of the patients were studied. One hundred 1.d was added to
the top of each gradient and centrifuged at 40,000 RPM in a
Beckman SW 41 rotor (Beckman Instruments, Inc., Fullerton,
California, USA) at 4°C for 20 hours. Radiolabeled 1gM and IgG
were used as marker proteins for 19S and 7S, respectively.
After centrifugation the gradient tubes were punctured and 22
fractions collected dropwise from the bottom of the tube. Any
precipitate on the bottom of the tube was resuspended in 0.1%
BSA in PBS. Fifty microliters of each fraction was analyzed
directly for iC3b-C3d neoantigen concentration as described
above.
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Statistical analysis
Student's t-test determined the significance between means.
The Pearson product—moment correlation (r) correlated the
individual proteins with iC3b-C3d neoantigen concentrations
[201. The significance of r was determined by applying the
calculated values to appropriate tables.
Results
Concentrations of the iC3b-C3d neoantigen for all 202 plas-
mas from the 81 IgA nephropathy patients and for the 31
healthy adult controls are shown in Figure 1. C3 activation, as
defined by a plasma iC3b-C3d neoantigen level above 22.6
pg/mI, was present in 37% (26 of 71) of the plasmas of pediatric
patients and 57% (74 of 131) of the plasmas of adult patients.
The mean iC3b-C3d neoantigen concentrations for both pediat-
ric and adult patients were significantly elevated as compared to
the healthy adult mean at 23.1 pg/ml (P < 0.005) and 29.2 jsg/ml
(P < 0.005), respectively. In addition, the mean concentration
was significantly higher for the adult patients as compared to
the pediatric patients (P < 0.05). Many of the patients had
significantly elevated iC3b-C3d concentrations in some, but not
all, of their serial plasmas. Seventy—three percent (40 of 55) of
the adult and 57% (16 of 28) of the pediatric patients had C3
activation demonstrated at least once. However, eight of 30
patients with at least three serial iC3b determinations never
exhibited C3 activation.
C4 activation as assessed by the area C4d/area C4 ratio for
193 plasmas is shown in Figure 2. Twenty percent (26 of 130) of
plasmas from adults and 5% (3 of 63) of the plasmas from
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Fig. 1. iC3b-C3d neoantigen concentration in jg/ml equivalents are
shown for control and patient plasmas. Mean standard error are
shown for both groups.
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pediatric patients had C4 activation. C4 activation was detected
on at least one occasion for 28% (15 of 54) of the adult and 11%
(3 of 28) of the pediatric patients. Of 96 plasmas in which
iC3b-C3d neoantigen concentration was significantly elevated
and area C4d/area C4 determined, 21(22%) had elevated and 75
(78%) had normal C4dIC4 ratios.
Except for one patient with a familial partial—factor H-
deficiency [13], plasma concentrations of C3, B, H and I were
normal or increased. The iC3b-C3d neoantigen concentration
weakly correlated with plasma concentrations of C3 (r =0.18),
B (r = 0.23), H (r = 0.24) and I (r = 0.22). Additionally, plasma
iC3b-C3d neoantigen weakly correlated with IgA concentra-
tions (r = 0.22). Degree of proteinuria, presence of chronic
renal insufficiency, or history of macroscopic hematuria did not
correlate with the iC3b-C3d neoantigen concentration.
Sucrose gradient ultracentrifugation studies on plasmas from
three patients with significant elevation of iC3b-C3d neoantigen
concentration showed distinctly different patterns (Fig. 3). One
patient had iC3b-C3d neoantigen present only in a low
molecular—weight peak corresponding to C3d or C3dg, while
another had iC3b-C3d neoantigen only in the 7S peak, possibly
representing iC3b or C3d bound to immunoglobulin. The third
showed iC3b-C3d in both peaks. No significant iC3b-C3d
neoantigen was detectable with size greater than 7S in these
patients.
Discussion
Activation of C3 by the classical or the alternate pathway
generates C3a anaphylatoxin and C3b which have many impor-
tant biological functions [21]. H and I subsequently inactivate
Fig. 3. iC3b-C3d neoantigen concentration in sucrose gradient frac-
tions are shown for three patients. Two patients' serums, shown in the
top and bottom panels, have a single peak occurring in different
fractions. The third individual's serum, shown in the middle panel has
two peaks. Arrows depict the fractions in which the peak for the 19S
and 7S markers occurred.
C3b by proteolytic cleavage of the alpha chain of C3b, thereby
producing iC3b [22]. Further proteolytic activity generates
several fragments of iC3b, including C3c, C3dg, C3d, C3g and
C3e [23]. Our monoclonal antibody detects an antigenic deter-
minant fully expressed only after iC3b is produced. iC3b, as
well as C3dg and C3d express this antigen.
The assay for detection of C3 activation in our study may
offer certain advantages over other assays [24—271. Since our
radioimmunoassay directly measures activated and inactivated
C3, a normal range can be accurately established and low levels
of activation detected. Previous assays have relied upon immu-
nochemical measurement of C3d [24, 25], altered electropho-
retic mobility of C3 [26], or two dimensional immunoelectro-
phoresis [27]. Since polyclonal antibodies to C3d always react
with C3 and C3b, these larger molecules must be removed by
precipitation with polyethylene glycol. This step introduces an
important potential error. The larger C3 activation fragments,
such as iC3b, may precipitate as well, thereby underestimating
C3 activation [28]. The semi-quantitative electrophoretic meth-
ods cannot easily assess small amounts of C3 activation.
Our data indicate that, despite normal or elevated plasma
levels of individual complement proteins, complement activa-
tion commonly occurs in patients with IgA nephropathy.
Lagrue et al [10] found mild, but significant elevation of the
plasma concentrations of the C3 activation fragment C3d in
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Fig. 2. C4d/C4 ratios are shown for control and patient plasmas.
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five of ten patients with IgA nephropathy. In addition, these
investigators found C3d in patients with hypocomplement-
emic glomerulonephritides as well as several types of non-
hypocomplementemic glomerular disorders such as membra-
nous nephropathy and focal segmental glomeruloscierosis.
Similarly a recent report by Solling showed significant amounts
of C3d in the plasma of five of 11 patients with IgA nephrop-
athy, as well as others with a variety of glomerular diseases
[11]. Thus, C3 activation appears to occur more commonly in
some glomerular diseases than previously appreciated and is
certainly not specific for IgA nephropathy.
Nevertheless, complement activation through the alternative
pathway has been frequently postulated as a pathogenically
important factor in IgA nephropathy U, 21. Although the IgA
aggregates or myeloma complexes may not be comparable to in
vivo IgA-containing circulating immune complexes, these in
vitro studies have shown activation of the alternative comple-
ment pathway [29—33]. IgA-containing circulating immune com-
plexes are frequent in patients with IgA nephropathy [34—38]
and such complexes could cause the complement activation
found in our patients. Most of our patients with complement
activation had elevated plasma iC3b-C3d neoantigen concentra-
tions with no C4 activation. However, the finding of C4
activation in 20% of our adult patients indicate that complement
activation may sometimes occur through the classical pathway.
Support of these data is the demonstration of C4 binding
protein, the classical pathway regulatory protein, in the
mesangia of some patients with IgA nephropathy [391.
Elevated plasma C3d concentrations decreased promptly
with plasmapheresis in patients with IgA nephropathy and
cellular glomerular crescent [40]. Plasmas from our patients
were usually obtained at the time of routine office visits.
Although many patients had significant proteinuria or chronic
renal insufficiency, we could not correlate these clinical param-
eters with the iC3b-C3d neoantigen concentrations. However,
IgA nephropathy causes slowly progressive chronic renal insuf-
ficiency in 20% of patients [4] and a longer follow—up may
reveal which patients with currently normal renal function will
progress to chronic renal insufficiency. Thus, it might be
unreasonable to expect iC3b-C3d neoantigen levels to correlate
with the clinical course in a study with brief follow—up, such as
ours. As shown in our sucrose—density gradient experiments,
our monoclonal antibody detects C3 activation fragments of
different sizes. More definitive clinicopathologic correlations
could become apparent as monoclonal antibodies to specific
fragments such as iC3b or C3d are developed.
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